• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

首例血清脂肪酶水平正常的度拉糖肽诱导的急性胰腺炎报告病例。

First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level.

作者信息

Shahbazi Mohammad, Qudsiya Zainab, Fahel Aboud, Amini Afshin, Tanoli Tariq

机构信息

Internal Medicine, St. Luke's Hospital, Chesterfield, USA.

Endocrinology, Diabetes and Metabolism, St. Luke's Hospital, Chesterfield, USA.

出版信息

Cureus. 2023 Jun 17;15(6):e40576. doi: 10.7759/cureus.40576. eCollection 2023 Jun.

DOI:10.7759/cureus.40576
PMID:37465801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10351928/
Abstract

Dulaglutide is being extensively used for non-insulin-dependent diabetes mellitus and congestive heart failure and is also being used as an off-label weight loss aid. Due to its wide use, we had to shed some light on this rare finding of normal lipase level in a patient with signs and symptoms suggestive of acute pancreatitis. A high index of clinical suspicion for acute pancreatitis despite normal lipase should warrant a low threshold for radiological imaging to rule it out.

摘要

度拉糖肽被广泛用于非胰岛素依赖型糖尿病和充血性心力衰竭，也被用作非标签减肥辅助药物。由于其广泛使用，我们不得不对一名有急性胰腺炎体征和症状但脂肪酶水平正常的罕见病例进行一些说明。尽管脂肪酶正常，但对急性胰腺炎的高度临床怀疑应促使对其进行放射学检查以排除该病的阈值降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020a/10351928/c929f8bc6576/cureus-0015-00000040576-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020a/10351928/c929f8bc6576/cureus-0015-00000040576-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020a/10351928/c929f8bc6576/cureus-0015-00000040576-i01.jpg

相似文献

1
First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level.首例血清脂肪酶水平正常的度拉糖肽诱导的急性胰腺炎报告病例。
Cureus. 2023 Jun 17;15(6):e40576. doi: 10.7759/cureus.40576. eCollection 2023 Jun.
2
Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report.度拉糖肽（度易达）诱发的急性胰腺炎：一例报告
Cureus. 2023 May 6;15(5):e38630. doi: 10.7759/cureus.38630. eCollection 2023 May.
3
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.在英国，每周一次司美格鲁肽与艾塞那肽延长释放、度拉糖肽和利拉鲁肽的相对控制成本分析。
Adv Ther. 2020 Mar;37(3):1248-1259. doi: 10.1007/s12325-020-01242-z. Epub 2020 Feb 11.
4
Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.在3期临床试验中，日本2型糖尿病患者接受每周一次0.75毫克度拉鲁肽治疗长达52周的胰腺安全性。
Endocr J. 2017 Feb 27;64(2):191-206. doi: 10.1507/endocrj.EJ16-0365. Epub 2016 Nov 15.
5
Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.法国2型糖尿病患者中GLP-1受体激动剂治疗模式及持续性：一项回顾性队列分析
Diabetes Ther. 2021 May;12(5):1553-1567. doi: 10.1007/s13300-021-01055-5. Epub 2021 Apr 17.
6
Tirzepatide (Mounjaro) for type 2 diabetes.替尔泊肽（Mounjaro）用于治疗2型糖尿病。
Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-107.
7
Drugs for type 2 diabetes.2型糖尿病药物。
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-184.
8
Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.在美国真实世界环境中，司美格鲁肽每周一次用药的持续性和依从性与其他胰高血糖素样肽-1受体激动剂用于2型糖尿病患者的比较
Diabetes Ther. 2021 May;12(5):1475-1489. doi: 10.1007/s13300-021-01053-7. Epub 2021 Apr 10.
9
Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.在丹麦环境下，每周一次司美格鲁肽与度拉鲁肽、艾塞那肽缓释剂、利拉鲁肽和利司那肽治疗2型糖尿病患者的成本效益分析
Diabetes Ther. 2019 Aug;10(4):1297-1317. doi: 10.1007/s13300-019-0630-6. Epub 2019 May 16.
10
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.度拉糖肽每周 1 次给药开发计划中胰腺安全性评估。
Diabetes Care. 2017 May;40(5):647-654. doi: 10.2337/dc16-0984. Epub 2017 Mar 10.

引用本文的文献

1
The effect of incretin-based drugs on the riks of acute pancreatitis: a review.基于肠促胰岛素的药物对急性胰腺炎风险的影响：一项综述。
J Diabetes Metab Disord. 2024 May 5;23(1):487-495. doi: 10.1007/s40200-024-01430-6. eCollection 2024 Jun.

本文引用的文献

1
Acute Interstitial Pancreatitis With a Normal Lipase Level in the Background of Inflammatory Bowel Disease: A Case Report.炎症性肠病背景下脂肪酶水平正常的急性间质性胰腺炎：一例报告
Cureus. 2021 Jul 16;13(7):e16417. doi: 10.7759/cureus.16417. eCollection 2021 Jul.
2
A Review of Acute Pancreatitis.急性胰腺炎综述
JAMA. 2021 Jun 15;325(23):2402. doi: 10.1001/jama.2021.6012.
3
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.美国胃肠道、肝脏和胰腺疾病的负担和成本：2018 年更新。
Gastroenterology. 2019 Jan;156(1):254-272.e11. doi: 10.1053/j.gastro.2018.08.063. Epub 2018 Oct 10.
4
Lipase or amylase for the diagnosis of acute pancreatitis?脂肪酶还是淀粉酶用于诊断急性胰腺炎？
Clin Biochem. 2017 Dec;50(18):1275-1280. doi: 10.1016/j.clinbiochem.2017.07.003. Epub 2017 Jul 16.
5
A rare entity in ED: Normal lipase level in acute pancreatitis.急诊科的一种罕见情况：急性胰腺炎时脂肪酶水平正常。
Turk J Emerg Med. 2016 Mar 10;16(1):32-4. doi: 10.1016/j.tjem.2014.09.001. eCollection 2016 Mar.
6
Acute pancreatitis with normal lipase and amylase: an ED dilemma.脂肪酶和淀粉酶正常的急性胰腺炎：急诊科的难题
Am J Emerg Med. 2016 Nov;34(11):2254.e3-2254.e6. doi: 10.1016/j.ajem.2016.05.023. Epub 2016 May 12.
7
Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.度易达（度拉糖肽）：一种新型胰高血糖素样肽-1（GLP-1）受体激动剂，获批用于2型糖尿病患者的治疗，每周皮下注射一次 。
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):131-4.
8
Drug-induced acute pancreatitis: a review.药物性急性胰腺炎：综述
Ochsner J. 2015 Spring;15(1):45-51.
9
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.利拉鲁肽与胰腺炎之间是否存在关联？对已完成的利拉鲁肽 2 型糖尿病临床试验的汇总和患者水平数据进行的事后回顾。
Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12.
10
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.肠降血糖素治疗与 2 型糖尿病患者胰腺炎风险：随机和非随机研究的系统评价和荟萃分析。
BMJ. 2014 Apr 15;348:g2366. doi: 10.1136/bmj.g2366.